Last reviewed · How we verify

Harbour BioMed (Guangzhou) Co. Ltd. — Portfolio Competitive Intelligence Brief

Harbour BioMed (Guangzhou) Co. Ltd. pipeline: 0 marketed, 0 filed, 2 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 2 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
HBM9036 0.25% Ophthalmic Solution HBM9036 0.25% Ophthalmic Solution phase 3 C5a receptor antagonist C5aR (C5a receptor) Ophthalmology
HBM9161 Injection (680mg) HBM9161 Injection (680mg) phase 3 PD-L1 inhibitor PD-L1 Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Ascletis Pharmaceuticals Co., Ltd. · 1 shared drug class
  2. Assistance Publique Hopitaux De Marseille · 1 shared drug class
  3. Astellas Pharma Europe B.V. · 1 shared drug class
  4. Astellas Pharma Inc · 1 shared drug class
  5. AstraZeneca · 1 shared drug class
  6. Biocad · 1 shared drug class
  7. CStone Pharmaceuticals · 1 shared drug class
  8. 3D Medicines (Sichuan) Co., Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Harbour BioMed (Guangzhou) Co. Ltd.:

Cite this brief

Drug Landscape (2026). Harbour BioMed (Guangzhou) Co. Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/harbour-biomed-guangzhou-co-ltd. Accessed 2026-05-17.

Related